Context Therapeutics (CNTX) Enterprise Value (2020 - 2026)
Context Therapeutics (CNTX) posted Enterprise Value of -$54.5 million for Q1 2026, up 17.37% sequentially from -$66.0 million in Q4 2025, and up 38.97% YoY from -$39.2 million in Q1 2025.
Context Therapeutics (CNTX) Enterprise Value (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$54.5 million in Q1 2026.
- Quarterly Enterprise Value rose 38.97% year-over-year to -$54.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.5 million (up 38.97% YoY) and the FY2025 annual result came in at -$66.0 million, up 30.11% from the prior year.
- Enterprise Value grew to -$54.5 million in Q1 2026 per CNTX's latest filing, from -$66.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$10.1 million in Q1 2024 and troughed at -$101.5 million in Q2 2024.
- A 5-year average of -$53.9 million and a median of -$45.7 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2024: Enterprise Value tumbled 9750.0% in 2022, then jumped 66.11% in 2024.
- Over 5 years, Enterprise Value stood at -$35.5 million in 2022, then jumped by 59.29% to -$14.4 million in 2023, then sank by 553.5% to -$94.4 million in 2024, then jumped by 30.11% to -$66.0 million in 2025, then grew by 17.37% to -$54.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$54.5 million, -$66.0 million, and -$76.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 2.12 Bn |
| 10 | Context Therapeutics | 48.40 Mn | 48.40 Mn | - | -43.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.00 Mn |
| Mar 31, 2026 | -54.53 Mn |
| Dec 31, 2025 | -66.00 Mn |
| Sep 30, 2025 | -76.94 Mn |
| Jun 30, 2025 | -83.52 Mn |
| Mar 31, 2025 | -89.35 Mn |
| Dec 31, 2024 | -94.43 Mn |
| Sep 30, 2024 | -84.80 Mn |
| Jun 30, 2024 | -101.54 Mn |
| Mar 31, 2024 | -10.10 Mn |
| Dec 31, 2023 | -14.45 Mn |
| Sep 30, 2023 | -21.70 Mn |
| Jun 30, 2023 | -25.10 Mn |
| Mar 31, 2023 | -29.80 Mn |
| Dec 31, 2022 | -35.50 Mn |
| Sep 30, 2022 | -39.40 Mn |
| Jun 30, 2022 | -42.90 Mn |
| Mar 31, 2022 | -45.70 Mn |
| Dec 31, 2021 | -49.69 Mn |
| Sep 30, 2021 | -400,000.00 |